These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 35249077)

  • 1. [Current Status and Future Perspectives of Molecular Targeted Therapies for Lung Cancer].
    Suda K; Mitsudomi T
    Kyobu Geka; 2022 Jan; 75(1):53-66. PubMed ID: 35249077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
    Benjamin DJ; Haslam A; Gill J; Prasad V
    Cancer Med; 2022 Sep; 11(18):3417-3424. PubMed ID: 35315222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer.
    Grant MJ; Woodard GA; Goldberg SB
    Hematol Oncol Clin North Am; 2023 Jun; 37(3):513-531. PubMed ID: 37024389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
    Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
    Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
    Melosky B; Wheatley-Price P; Juergens RA; Sacher A; Leighl NB; Tsao MS; Cheema P; Snow S; Liu G; Card PB; Chu Q
    Lung Cancer; 2021 Oct; 160():136-151. PubMed ID: 34353680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
    Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer.
    Lim SM; Lee JB; Oya Y; Nutzinger J; Soo R
    JCO Oncol Pract; 2024 Jan; 20(1):47-56. PubMed ID: 37733983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 11. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations.
    Tan AC; Tan DSW
    J Clin Oncol; 2022 Feb; 40(6):611-625. PubMed ID: 34985916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives.
    Imyanitov EN; Iyevleva AG; Levchenko EV
    Crit Rev Oncol Hematol; 2021 Jan; 157():103194. PubMed ID: 33316418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
    Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
    Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel targets in non-small cell lung cancer: ROS1 and RET fusions.
    Gainor JF; Shaw AT
    Oncologist; 2013; 18(7):865-75. PubMed ID: 23814043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapy for Non-Small Cell Lung Cancer: First Line and Beyond.
    Brea E; Rotow J
    Hematol Oncol Clin North Am; 2023 Jun; 37(3):575-594. PubMed ID: 37024384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High Discrepancy of Driver Mutations in Patients with NSCLC and Synchronous Multiple Lung Ground-Glass Nodules.
    Wu C; Zhao C; Yang Y; He Y; Hou L; Li X; Gao G; Shi J; Ren S; Chu H; Zhou C; Zhang J; Schmid-Bindert G
    J Thorac Oncol; 2015 May; 10(5):778-783. PubMed ID: 25629635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Cancer Therapy Targeting Fusion Genes in Lung Cancer].
    Tateishi A; Goto Y
    Gan To Kagaku Ryoho; 2022 Oct; 49(10):1043-1047. PubMed ID: 36281592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Targets Beyond the Big 3.
    Reckamp KL
    Thorac Surg Clin; 2020 May; 30(2):157-164. PubMed ID: 32327174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Driver genes expression and clinical characteristics of targeted therapy in non-small cell lung cancer in Yunnan-Kweichow Plateau].
    Lin YP; Li Q; Ma LY; Liu X; Dai M; Wang XX; Li HS; Liu JX; Shen ZH; Guo YJ; Du YX; Yang RJ; Huang YC; Zhou YC
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):735-740. PubMed ID: 32988155
    [No Abstract]   [Full Text] [Related]  

  • 20. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.